Persistent Identifier
|
doi:10.11588/data/AWIFGR |
Publication Date
|
2023-11-25 |
Title
| Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] |
Author
| Vardarli, Irfan (Heidelberg University, 5th Medical Department, Division of Endocrinology and Diabetes, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany) - ORCID: 0009-0009-2554-0971
Tan, Susanne (University of Duisburg-Essen, Department of Endocrinology, Diabetes and Metabolism, Clinical Chemistry – Division of Laboratory Research; Endocrine Tumor Center at WTZ/Comprehensive Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany)
Brandenburg, Tim (University of Duisburg-Essen, Department of Endocrinology, Diabetes and Metabolism, Clinical Chemistry – Division of Laboratory Research; Endocrine Tumor Center at WTZ/Comprehensive Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany)
Weidemann, Frank (Ruhr-University Bochum, Department of Medicine I, Klinikum Vest, Knappschaftskrankenhaus Recklinghausen, Academic Teaching Hospital, Ruhr-University Bochum, Recklinghausen, Germany)
Görges, Rainer (University of Duisburg Essen, Department of Nuclear Medicine, University Hospital Essen, University of Duisburg Essen, Essen, Germany)
Herrmann, Ken (University of Duisburg Essen, Department of Nuclear Medicine, University Hospital Essen, University of Duisburg Essen, Essen, Germany)
Führer, Dagmar (University of Duisburg-Essen, Department of Endocrinology, Diabetes and Metabolism, Clinical Chemistry – Division of Laboratory Research; Endocrine Tumor Center at WTZ/Comprehensive Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany) |
Point of Contact
|
Use email button above to contact.
Vardarli, Irfan (5th Medical Department, Division of Endocrinology and Diabetes, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany) |
Description
| Supplemental Materials Abstract Context Few meta-analyses regarding the incidence of endocrine immune related adverse effects (eirAEs) have been published and many trials were published thereafter. Objective To assess the risk and incidence of eirAEs of any grade and grade 3-5 by immune checkpoint inhibitor (ICI) mono or combination-therapy in solid tumors current literature was updated in this comprehensive meta-analysis. Methods An electronic search using PubMed/Medline, Embase and the Cochrane Library was performed. Randomized controlled studies (RCT) assessing eirAEs under ICI-mono or ICI-combination therapy were selected. Stata software version 17 was used for statistical analyses and risk of bias was evaluated by using Review Manager version 5.3. Results 69 RCTs with 80 independent reports, involving 42,886 patients were included in the study. Meta-analysis revealed the following pooled estimates for the risk ratio and the incidence, respectively: for any grade hypothyroidism 7.81 (95% CI, 5.68-10.74, p< 0.0001) and 7.64% (95% CI, 6.23-9.17, p< 0.0001); significantly increased also for hyperthyroidism, hypophysitis/hypopituitarism and adrenal insufficiency; and for insulin-dependent diabetes mellitus 1.52 (95% CI, 1.07-2.18, p= 0.02), and 0.087% (95% CI, 0.019-0.189, p= 0.0006), respectively. Meta-regression showed that combination of ICIs (nivolumab plus ipilimumab and durvalumab plus tremelimumab, respectively) is an independent risk factor for any grade hypophysitis/hypopituitarism, and that ICI agent is an independent factor of risk for adrenal insufficiency, but that cancer type is not an independent risk factor for eirAEs. Conclusion We showed that risk, independent from cancer type, and incidence of eAEs are substantially increased under ICI therapy. Combination of ICIs is increasing the risk for eirAEs, in particular for hypophysitis/hypopituitarism. (2023-11-23) |
Subject
| Medicine, Health and Life Sciences |
Keyword
| Thyroid, check-point-inhibitors, endocrine adverse events |
Related Publication
| Vardarli, I., Tan, S., Brandenburg, T., Weidemann, F., Görges, R., Herrmann, K., & Führer, D. (2023). Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: A meta-analysis of randomized controlled trials. The Journal of Clinical Endocrinology & Metabolism, dgad670. https://doi.org/10.1210/clinem/dgad670 doi: 10.1210/clinem/dgad670 https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgad670/7423989 |
Language
| English |
Production Date
| 2023-11-23 |
Production Location
| Heidelberg University |
Deposit Date
| 2023-11-23 |